Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of Daphnetin

Drug Metabolism and Disposition

Volumn 38, Issue 6, 2010, Pages 973-980

  Liang, Si Cheng ^a,b   Ge, Guang Bo ^a   Liu, Hui Xin ^a,b   Zhang, Yan Yan ^a   Wang, Li Ming ^c   Zhang, Jiang Wei ^a   Yin, Lu ^a   Li, Wei ^a,b   Fang, Zhong Ze ^a,b   Wu, Jing Jing ^a   Li, Guo Hui ^a   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 O MONOGLUCURONIDE DAPHNETIN; 8 O MONOGLUCURONIDE DAPHNETIN; DAPHNETIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; PHENOL; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG GLUCURONIDATION; ENZYME ANALYSIS; FEMALE; HUMAN; INTESTINE; LIVER CLEARANCE; LIVER MICROSOME; MALE; MINIPIG; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; SPECIES DIFFERENCE;

AFRICAN AMERICANS; CHINA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MICROSOMES; SUBSTRATE SPECIFICITY; UMBELLIFERONES; URIDINE DIPHOSPHATE GLUCURONIC ACID;

RATTUS;

EID: 77952307459     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030734     Document Type: Article

References (40)

1. Antonio L, Grillasca JP, Taskinen J, Elovaara E, Burchell B, Piet MH, Ethell B, Ouzzine M, Fournel-Gigleux S, and Magdalou J (2002) Characterization of catechol glucuronidation in rat liver. Drug Metab Dispos 30:199-207.
2. Antonio L, Xu J, Little JM, Burchell B, Magdalou J, and Radominska-Pandya A (2003) Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. Arch Biochem Biophys 411:251-261.
3. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
4. Basu NK, Ciotti M, Hwang MS, Kole L, Mitra PS, Cho JW, and Owens IS (2004) Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem 279:1429-1441.
5. Cottiglia F, Loy G, Garau D, Floris C, Casu M, Pompei R, and Bonsignore L (2001) Antimicrobial evaluation of coumarins and flavonoids from the stems of Daphne gnidium L. Phytomedicine 8:302-305.
6. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
7. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:202-217.
8. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
9. Ebner T and Burchell B (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21:50-55. (Pubitemid 23052221)
10. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, and Thornes RD (1990) The pharmacology, metabolism, analysis, applications of coumarin and coumarin-related compounds. Drug Metab Rev 22:503-529.
11. Finn GJ, Creaven BS, and Egan DA (2004) Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem Pharmacol 67:1779-1788. (Pubitemid 38479856)
12. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
13. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, and Nicolaides DN (2004) Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. Curr Pharm Des 10:3813-3833. (Pubitemid 39409872)
14. Gaganis P, Miners JO, and Knights KM (2007) Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 73:1683-1691. (Pubitemid 46527548)
15. Guengerich PF (1989) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp 777-813, Raven Press, New York2E
16. Huang F, Tang LH, Yu LQ, Ni YC, Wang QM, and Nan FJ (2006) In vitro potentiation of antimalarial activities by daphnetin derivatives against Plasmodium falciparum. Biomed Environ Sci 19:367-370. (Pubitemid 44916213)
17. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
18. Lautala P, Ethell BT, Taskinen J, and Burchell B (2000) The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385-1389.
19. Liu HX, Liu Y, Zhang JW, Li W, Liu HT, and Yang L (2008) UDP-glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes. Drug Metab Dispos 36:1562-1569.
20. Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Almeida L, Wright LC, and Soares-Da-Silva P (2006) Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 34:1856-1862. (Pubitemid 44771713)
21. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
23. Mano Y, Usui T, and Kamimura H (2008) Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3β-glucuronidation between rats, dogs, and humans. J Pharm Sci 97:2805-2810.
24. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
26. Qu SY, Wu YJ, Wang YH, and Zuo YX (1983) Metabolism and pharmacokinetics of daphnetin. Yao Xue Xue Bao 18:496-500.
27. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
28. Shiratani H, Katoh M, Nakajima M, and Yokoi T (2008) Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
29. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
30. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1998) Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647-654. (Pubitemid 28480967)
31. Tachibana M, Tanaka M, Masubuchi Y, and Horie T (2005) Acyl glucuronidation of fluoroquinolone antibiotics by the UDP- glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 33:803-811. (Pubitemid 40686634)
32. Taylor S and Harker A (2006) Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 41:299-303.
33. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
34. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
35. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423. (Pubitemid 38420275)
36. Wang Q, Ye C, Jia R, Owen AJ, Hidalgo IJ, and Li J (2006) Inter-species comparison of 7-hydroxycoumarin glucuronidation and sulfation in liver S9 fractions. In Vitro Cell Dev Biol Anim 42:8-12.
37. Yang EB, Zhao YN, Zhang K, and Mack P (1999) Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. Biochem Biophys Res Commun 260:682-685.
38. Yeşilada E, Taninaka H, Takaishi Y, Honda G, Sezik E, Momota H, Ohmoto Y, and Taki T (2001) In vitro inhibitory effects of Daphne oleoides ssp. oleoides on inflammatory cytokines and activity-guided isolation of active constituents. Cytokine 13:359-364.
39. Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, et al. (2008) Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos 36:2292-2298.
40. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, and Yang L (2009) Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39:283-292.